4//SEC Filing
AZAB MOHAMMAD 4
Accession 0000950170-23-071929
CIK 0001582313other
Filed
Dec 19, 7:00 PM ET
Accepted
Dec 20, 5:04 PM ET
Size
10.6 KB
Accession
0000950170-23-071929
Insider Transaction Report
Form 4
AZAB MOHAMMAD
Director
Transactions
- Exercise/Conversion
Common Shares
2023-12-19$9.85/sh+3,497$34,445→ 74,225 total - Exercise/Conversion
Common Shares
2023-12-19$9.85/sh+823$8,107→ 70,728 total - Exercise/Conversion
Stock Option (Right to Buy)
2023-12-19−823→ 0 totalExercise: $9.85From: 2016-12-31Exp: 2024-01-13→ Common Shares (823 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2023-12-19−3,497→ 0 totalExercise: $9.85From: 2016-12-31Exp: 2024-01-13→ Common Shares (3,497 underlying)
Footnotes (2)
- [F1]The common shares issued as a result of the exercise are subject to the terms of a Lock-Up Agreement executed by the Reporting Person in favor of the underwriters of the Company's follow-on public offering in November 2023.
- [F2]The exercise price was converted to U.S. dollars from $10.78 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise.
Documents
Issuer
Xenon Pharmaceuticals Inc.
CIK 0001582313
Entity typeother
Related Parties
1- filerCIK 0001309653
Filing Metadata
- Form type
- 4
- Filed
- Dec 19, 7:00 PM ET
- Accepted
- Dec 20, 5:04 PM ET
- Size
- 10.6 KB